By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting out of Chapel Hill, North Carolina, by NewsRx editors, research stated, "The poor solubility of cisplatin (CDDP) often presents a major obstacle in the formulation of CDDP in nanoparticles (NPs) by traditional methods. We have developed a novel method for synthesizing CDDP NPs taking advantage of its poor solubility."
Our news journalists obtained a quote from the research from the University of North Carolina, "By mixing two reverse microemulsions containing KCl and a highly soluble precursor of CDDP, cis-diaminedihydroplatinum (II), we have successfully formulated CDDP NPs with a controllable size (in the range of 12-75 nm) and high drug loading capacity (approximately 80 wt.%). The formulation was done in two steps. The pure CDDP NPs were first stabilized for dispersion in an organic solvent by coating with 1, 2-dioleoyl-sn-glycero-3-phosphate (DOPA). Both x-ray photoelectron spectroscopy and H-1 NMR data confirmed that the major ingredient of the DOPA-coated NPs was CDDP. After purification, additional lipids were added to stabilize the NPs for dispersion in an aqueous solution. The final NPs contain a lipid bilayer coating and are named Lipid-Pt-Cl (LPC) NPs, which showed significant antitumor activity both in vitro and in vivo. Thus, CDDP precipitate serves as the major material for assembling the novel NPs."
According to the news editors, the research concluded: "This unique method of nanoparticle synthesis may be applicable in formulating other insoluble drugs."
For more information on this research see: Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. Journal of Controlled Release, 2014;174():137-142. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news journalists report that additional information may be obtained by contacting S.T. Guo, University of North Carolina, Eshelman Sch Pharm, Center Nanotechnol Drug Delivery, Chapel Hill, NC 27599, United States. Additional authors for this research include L. Miao, Y.H. Wang and L. Huang (see also Drugs and Therapies).
Keywords for this news article include: Antineoplastics, Pharmaceuticals, Cancer, Oncology, Cisplatin, Chapel Hill, Nanoparticle, United States, North Carolina, Nanotechnology, Alkylating Agents, Chlorine Compounds, Nitrogen Compounds, Platinum Compounds, Drugs and Therapies, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC